Oncimmune (LON:ONC) Shares Up 4.7% – Here’s What Happened

Oncimmune Holdings plc (LON:ONC)’s stock price rose 4.7% during trading on Monday . The stock traded as high as GBX 4.50 ($0.06) and last traded at GBX 4.50 ($0.06). Approximately 752,922 shares changed hands during trading, an increase of 79% from the average daily volume of 421,424 shares. The stock had previously closed at GBX 4.30 ($0.05).

Oncimmune Stock Down 2.5 %

The firm’s 50-day simple moving average is GBX 12.49 and its 200 day simple moving average is GBX 14.65. The company has a debt-to-equity ratio of -412.06, a quick ratio of 0.63 and a current ratio of 1.14. The stock has a market capitalization of £4.42 million, a P/E ratio of 0.44 and a beta of 1.19.

Oncimmune (LON:ONC) last issued its earnings results on Monday, February 10th. The company reported GBX (4.72) (($0.06)) earnings per share (EPS) for the quarter. Oncimmune had a net margin of 581.63% and a negative return on equity of 2,277.74%.

Oncimmune Company Profile

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.